VGLL4 and gastric cancer: Functional in vitro and in vivo studies linked aberrant activation of YAP/TAZ to the progression of gastric cancer (GC) [24], and the inhibition of the YAP/TAZ–TEAD interaction achieved with a Vgl-like-4—(VGLL4) mimicking peptide severely impaired GC cell survival [25].